Background: Statins have shown strong evidence of decrease in cardiovascular morbidity and mortality. Given the pleiotropic actions of statins, they are likely not only to improve the dyslipidaemia associated with PCOS but may also exert other beneficial metabolic and endocrine effects. Objectives: To assess the efficacy and safety of statins therapy for women polycystic ovary syndrome not actively trying to conceive. Methods: We searched randomised controlled trials which compared statin versus placebo or statin in combined with another drug versus another drug alone in patients with confirmed diagnosis of PCOS in the Cochrane Menstrual Disorders and Subfertility Group Trials Register (Issue 3, 2009), Cochrane Central Register of Controlled Trials (CENTRAL (Ovid), third quarter 2009), MEDLINE (1966 to September 2009), References of the identified articles were handsearched were for additional relevant studies. Data were collected and analysed using Rev Man 5. Results: Out of twelve studies indentified, two trials were fulfilling the criteria for inclusion in meta analysis. One of them was using atorvastatin (37 participants) other using simvastatin in combination with Oral Contraceptive Pill (OCP) (48 participants). Meta analysis showed that statin shown significant reduction in total testosterone level (WMD -0.93, 95% CI -1.24 to -0.88), total cholesterol level (WMD -0.89, 95% CI -1.19 to -0.58), LDL (WMD -0.82, 95% CI -1.19 0.49) and triglyceride (WMD -0.34, 95% CI -0.59 to -0.10). However, statins were not shown beneficial effect in improving fasting insulin, fasting glucose, corticotropic hormones level. There was no evidence of effects of statins on body mass index, body weight waist line. There was no evidence of improvement in menstrual cycle and/or hirsutism, but evidence was very limited. No serious adverse events were reported. Conclusions: Statin is effective improving lipid profile in patients with PCOS which ultimately have beneficial effect in treating parameters of metabolic syndrome associated with PCOS. However, no data is available of long term risk of cardiovascular risk profile in women with PCOS. Statins also reduce the biochemical parameter of hyperandrogaenemia (reducing level of total testosterone). However limited data available to show improvement in hirsutism, acne and menstrual cycle. There is no data regarding long term safety of statin in young women.